Navigation Links
BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Date:12/29/2008

BOTHELL, Wash., Dec. 29 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has joined the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, an international consortium of leading scientific, clinical, and commercial partners whose mission is to explore collaborative ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy.

Zbigniew "Ziggy" M. Szczepiorkowski, MD, PhD, co-chair of the BEST cellular therapy team and Associate Professor of Pathology and of Medicine at Dartmouth Medical School, commented on the addition of BioLife Solutions as a new corporate member of BEST by stating, "We're very pleased to welcome BioLife to the BEST Collaborative. BioLife joins other corporate members in the quest to advance the field of transfusion medicine and to work with world leading experts. Results from recent initial safety studies conducted by BioLife and submission of FDA Master Files understandably elevates the profile of the company in the field of transfusion medicine in the US and internationally. We look forward to mutually beneficial scientific collaboration with BioLife and other BEST corporate members to identify ways to extend the shelf-life and improve the transportation logistics as well as post-preservation viability and functional yield of transfusion-related source material and derived cell-based clinical products."

Mike Rice, BioLife's chairman and CEO, noted "Since its formation, the scientific members of BEST have collectively published over 50 peer reviewed scientific articles related to efforts to continually improve quality, safety and efficiency in transfusion medicine. W
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
2. BioLife Solutions Granted European Biopreservation Patent
3. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
4. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
5. BioLife Solutions Credit Facility Increased to $9 Million
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation
8. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
9. BioLife Solutions Expands Scientific Advisory Board
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... One of the most extensive, widely cited digital ... now available to high school and junior college students and ... international society for optics and photonics , announced today that ... Library available to high schools for free and two-year ... to all areas of life in today’s world,” said SPIE ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... VA (PRWEB) November 21, 2014 During ... who understood the need to surround himself with great ... CEO and entrepreneur, his friends often marveled at his ... he lived his life and -- even with his ... for the Alzheimer’s disease that would ultimately take his ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... , , , ... ADL), a US-based pharmaceutical company with major assets in China, announced today ... of the Company as " Radient Pharmaceuticals Corporation" . ... will be "RPC" . The Company has filed an ...
... , SEATTLE, Sept. 18 Omeros Corporation ... 6.82 million shares of its common stock. Omeros is ... products focused on inflammation and disorders of the central nervous ... for the initial public offering is $10.00 to $12.00 per ...
... , , SAN MATEO, ... a biopharmaceutical company focused on developing and commercializing novel pain management ... is scheduled to present at the UBS Global Life Sciences Conference, ... City. , , Mr. DiTonno and Stephen ...
Cached Biology Technology:AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 2AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 3AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 4AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 5Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3NeurogesX to Present at UBS Global Life Sciences Conference 2NeurogesX to Present at UBS Global Life Sciences Conference 3
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... recorded during a record-setting expedition have yielded new insights ... in the cold, dark, and highly pressurized habitats of ... Natalya Gallo of Scripps Institution of Oceanography at ... DEEPSEA CHALLENGE expedition, a project led by James Cameron ...
... his doctoral student Nicole Bance are among an international group ... compounds capable of killing the influenza virus. , Working ... can be a killer, the scientists have advanced previous researchers, ... influenza replicates and spreads. , Their new compounds will ...
... 21, 2013) Cardiovascular disease specialists at Florida Hospital Pepin ... with the University of South Florida announced they have enrolled ... gene therapy for the treatment of heart failure after ischemic ... tissue by encouraging the body to deploy more stem cells ...
Cached Biology News:Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 2Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 3Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Biology Products: